Get the Stockscreener App
21.57
0.19%
0.04
After Hours:
21.57
Jasper Therapeutics Inc stock is traded at $21.57, with a volume of 202.27K.
It is up +0.19% in the last 24 hours and up +2.81% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$21.53
Open:
$21.12
24h Volume:
202.27K
Relative Volume:
0.81
Market Cap:
$323.58M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-21.79
EPS:
-0.99
Net Cash Flow:
$-52.33M
1W Performance:
+4.71%
1M Performance:
+2.81%
6M Performance:
-1.33%
1Y Performance:
+290.05%
1-Day Range:
$21.00
$22.20
1-Week Range:
$19.41
$23.11
52-Week Range:
$5.00
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
21.57 | 323.58M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Wellington Management Group LLP Buys New Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
(JSPR) Trading Signals - Stock Traders Daily
Fmr LLC Makes New $722,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics' SWOT analysis: briquilimab's promise lifts stock outlook - Investing.com India
Jasper Therapeutics' SWOT analysis: briquilimab's promise lifts stock outlook By Investing.com - Investing.com South Africa
Head to Head Contrast: Jasper Therapeutics (NASDAQ:JSPR) versus Immunovant (NASDAQ:IMVT) - Defense World
Jasper Therapeutics COO Mahal Singh sells $19,899 in stock - Investing.com
Jasper Therapeutics COO Mahal Singh sells $19,899 in stock By Investing.com - Investing.com UK
Verition Fund Management LLC Invests $477,000 in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $73.38 - Defense World
When (JSPR) Moves Investors should Listen - Stock Traders Daily
BMO Capital Markets Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR) - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Jasper Therapeutics (NASDAQ:JSPR) versus PharmaCyte Biotech (OTCMKTS:PMCBD) Head to Head Comparison - Defense World
BMO Capital Initiates Coverage of Jasper Therapeutics (JSPR) with Outperform Recommendation - MSN
BMO Capital Markets Begins Coverage on Jasper Therapeutics (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics shares rise on BMO's Outperform rating By Investing.com - Investing.com Canada
Samsara BioCapital LLC Boosts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 10.2% in November - Defense World
Jasper Therapeutics, Inc. Doses First Patient in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma - Marketscreener.com
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma - GlobeNewswire
Jasper Therapeutics Launches Phase 1b/2a Asthma Trial, Expands Briquilimab Program | JSPR Stock News - StockTitan
Braidwell LP Invests $9.09 Million in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily
Great Point Partners LLC Sells 79,635 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - MarketBeat
Addiction Therapeutics Market to Observe Strong Growth by 2030| Abbott, Denali Therapeutics - Newstrail
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma (NASDAQ:JSPR) - Seeking Alpha
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate - Yahoo Finance
Is Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes mast cell stock - Investing.com
Jasper Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Jasper Therapeutics to Present Briquilimab Updates at Major Healthcare Conferences | JSPR Stock News - StockTitan
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $74.86 - MarketBeat
Stifel Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - MSN
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) News: Jasper Therapeutics, Inc. Reports Third Quarter 2024 Results - Defense World
Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise - GuruFocus.com
Jasper Therapeutics Advances in Antibody Therapy Development - TipRanks
Jasper Therapeutics Inc (JSPR) Quarterly 10-Q Report - Quartzy
McDonald's Corp (MCD-N) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
TSX Oil and Gas EW Index (TXOE) QuotePress Release - The Globe and Mail
Nasdaq Other Finance Index (OFIN) QuotePress Release - The Globe and Mail
(JSPR) Long Term Investment Analysis - Stock Traders Daily
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Net Present Value Model: Jasper Therapeutics Inc’s Briquilimab - GlobalData
JSPRJasper Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Long Term Trading Analysis for (JSPR) - Stock Traders Daily
Jasper Therapeutics' SWOT analysis: briquilimab stock shows promise amid challenges - Investing.com
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):